DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here
A collection of candid interviews from those in the healthcare ecosystem

This new video series brought to you by Decision Resources Group, is a collection of candid interviews with key leaders and stakeholders in the healthcare ecosystem that examines the business challenges and opportunities the industry currently faces. Every season will explore different parts of the healthcare continuum including R&D, clinical, tech focused businesses, commercial pharma, CROs, contract manufacturers of APIs and biosimilars, regulators and public health experts.

A novel approach to treating neurodegenerative disease
Dr. Leen Kawas, Ph.D., President and CEO, Athira Pharma
How Glympse Bio oversubscribed their Series B funding amidst the pandemic
Caroline Loew, Ph.D., President & CEO, Glympse Bio
Utilizing pluripotent stem cells in cell therapy
Brian Culley, CEO Lineage Cell Therapeutics
Pivoting a product launch during the pandemic
Bryan Witherbee, President and CEO, Adarza BioSystems
Possible treatment for COVID-19 related respiratory failure
Jonathan C. Javitt, CEO, NeuroRx
Transforming the treatment of cancer with oncolytic viruses
Stephen J. Russell, CEO, Vyriad
Early planning key to successful access and product launch
Alison Kneen, Senior Vice President, Decision Resources Group
COVID-19, multi-stem clinical trials and a new way of fundraising
Gil Van Bokkelen, Founder, Chairman and CEO at Athersys Inc.
Maximising R+D efforts through better epidemiology understanding
Mike Hughes, Senior Director of Epidemiology, DRG
Addressing strategic challenges for biotech companies
Dr Srikanth Rajagopal, Consulting Partner, DRG
How including patients can help with the fight against Parkinson’s Disease
Russ Bradford & Charlotte Allen, Co-Founders, Parkinson’s Concierge
Bringing together minds to combat COVID-19
Sir Mene Pangalos, Executive Vice President, AstraZeneca
An unprecedented time of scientific innovation
Houman Ashrafian, Managing Partner, SV Health Investors
Securing investments amidst COVID-19 and Brexit uncertainties
Hakan Goker, Vice President, M Ventures
The advantages of onsite manufacturing facilities for clinical trials
Bill Newell, CEO, Sutro Biopharma
Bringing new medicines to market despite subjective endpoints
Seth Lederman, CEO & Chairman, Tonix Pharmaceuticals
Revolutionising the neurodegenerative space – fundraising, development & beyond
Sanjay Kakkar, CEO, Tranquis Therapeutics

How COVID is reshaping global policy and what it means for market access
Steve Edgar and Judith Rubinstein, DRG market access experts

Will healthcare change after COVID-19?
Richard Erwin, General Manager and Managing Director, Roche Products Ltd (UK)

Becoming one of the leaders in developing COVID-19 diagnostics
Mark Stevenson, Vice President and Chief Operation Officer, Thermo Fisher Scientific

Collaborating with officials to continue developments
Joe Panetta, President and CEO, BIOCOM

COVID-19 and the new digital world
Ann Limb, Chair of the Scout Association, Scout Association

An update from biopharma’s hotspot
Bob Coughlin, CEO, MassBio

The past, present and future of next generation sequencing
Nick McCooke, CEO, Longas Technologies

Using a problem centric approach to build programs
Eric Elenko, Chief Innovation Officer, PureTech

How innovation can continue to evolve and shape the pharma space
Daphne Zohar, Founder & CEO, PureTech

The pandemic, politicians and science
Baroness Susan Greenfield, Founder & CEO, Neuro-Bio

How China has grown through innovation to rival the US market
Christian Hogg, CEO and Executive Director, Chi-Med

Physicians find new ways to share best practice
Mike Clayman, CEO and Co-Founder, Flexion Therapeutics

The effects of COVID-19 on worldwide oncology clinical trials
Steve Fruchtman, Onconova Therapeutics Inc

COVID-19 continues to disrupt patient care
John Jaeger, Decision Resources Group

To know COVID-19 is to know medicine
Dr. RJ Tesi, INmune Bio

Impact of COVID-19 on the development of CAR T-cell therapies
Dana Gheorghe, Decision Resources Group

Wuhan experience shapes the new normal for healthcare
Christian Hogg, Hutchison China MediTech

Creating a collaborative toolbox to fight COVID-19
Dr. Werner Lanthaler, Evotec

If you have a question for our guest, host or DRG please submit it here.